Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 10, Issue 12, 2010, Pages 1789-1797

  Fox, Edward J ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

alemtuzumab; autoimmune; monoclonal antibody; multiple sclerosis; relapse; remission

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; METHYLPREDNISOLONE;

CLINICAL TRIAL; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; HERPES SIMPLEX; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRURITUS; RESPIRATORY TRACT INFECTION; REVIEW; THYROID DISEASE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ATROPHY; BRAIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE;

EID: 78649505255     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.135     Document Type: Review

References (44)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354(9), 942-955 (2006).
2. Compston A, Coles A. Multiple sclerosis. Lancet 372, 1502-1517 (2008).
3. ® (IFNb-1a) prescribing information. October (2008).
4. ® (IFN-b1b) prescribing information. April (2008).
5. ® (IFN-b1a) prescribing information. December (2008).
6. ® (glatiramer acetate) prescribing information. February (2009).
7. ® (natalizumab) prescribing information. October (2008).
8. Coles A. Multiple Sclerosis. In: Contemporary Treatments in Neurology. Scolding N (Ed.). Butterworth Heinemann, MA, USA, 130-146 (2001).
9. ® (mitoxantrone) prescribing information. August (2008).
10. Treadaway K, Cutter G, Salter A et al. Factors that infuence adherence with disease-modifying therapy in MS. J. Neurol. 256, 568-76 (2009).
11. Moses H, Brandes D. Managing the adverse effects of disease-modifying agents used for the treatment of multiple sclerosis. Curr. Med. Res. Opin. 24(9), 2679 (2008).
12. Frohman EM, Brannon K, Alexander S et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult. Scler. 10(3), 302-307 (2004).
13. Galetta S, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profles. CNS Drugs 19(3), 239-252 (2005).
14. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52, 1072-1074 (1999).
15. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther. 28(4), 461-474 (2006).
16. Linda H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361(11), 1081-1087 (2009).
17. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr. Opin. Neurol. 22, 226-232 (2009).
18. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35(3), 118-127 (1990).
19. Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253(1), 98-108 (2006).
20. Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46(3), 296-304 (1999).
21. Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344, 298-301 (1994).
22. Ashton DS, Beddell CR, Cooper DJ et al. Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H. Anal. Chem. 67(5), 835-842 (1995).
23. Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int. Immunol. 7(1), 69-77 (1995).
24. Wing MG, Moreau T, Greenwood J et al. Mechanism of frst-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98(12), 2819-2826 (1996).
25. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-defcient cells. Immunology 95(3), 427-436 (1998).
26. Moreau T, Coles A, Wing M et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119(Pt 1), 225-237 (1996).
27. Tawara T, Hasegawa K, Sugiura Y et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J. Immunol. 180(4), 2294-2298 (2008).
28. Hu Y, Turner M, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128(2), 260-270 (2009).
29. ®) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br. J. Clin. Pharmacol. 64(3), 278-291 (2007).
30. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon b-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786-1801 (2008).
31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452 (1983).
32. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691-1695 (1999). (Pubitemid 29533060)
33. Selma JK. Alemtuzumab signifcantly increases the proportion of clinically disease-free patients with relapsing remitting MS compared to subcutaneous interferon b-1a: results from a Phase 2 study. Mult. Scler. 14(Suppl. 1), S5-S27 (2008). Presented at: World Congress on Treatment and Research in Multiple Sclerosis. Montreal, Canada, 17-20 September (2008).
34. Vladic A. Early treatment of multiple sclerosis with alemtuzumab signifcantly improves patient functioning and self-reported quality of life compared to SC interferon b-1a. Mult. Scler. 14, (P528) (2008). Presented at: World Congress on Treatment and Research in Multiple Sclerosis. Montreal, Canada, 17-20 September (2008).
35. Fox E, Mayer L, Sullivan H, O'Donnell L, Melia K, Lake S. Two-year results with alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed b-interferon therapies. Mult. Scler. 13, (P558) (2007). Presented at: 23rd Congress of the European Committee for Treatment of Research in Multiple Sclerosis. Prague, Czech Republic, 11-14 October (2007).
36. ® Effcacy in Multiple Sclerosis): design of a Phase 3, open-label, rater-blinded study of alemtuzumab in treatment-naive patients with relapsing MS. Neurology 70, (P02.171) (2008). Presented at: 60th Annual Meeting of the American Academy of Neurology. IL, USA, 12-19 April (2008).
37. ® Effcacy in Multiple Sclerosis): updated design of a Phase 3, open-label, rater-blinded study of alemtuzumab in patients with MS who have relapsed on therapy. J. Neur. Presented at: 19th Meeting of the European Neurological Society. Milan, Italy, 19-23 June (2009).
38. Sullivan H and the CAMMS223 Study Group. ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: case reports and risk management plan implementation. Neurology (Suppl. 1), A206 (2007). Presented at: 59th Annual Meeting of the American Academy of Neurology. MA, USA, 28 April-5 May (2007).
39. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism. Arthritis Rheum. 44, 1977-1983 (2001).
40. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as frst-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768-773 (2002).
41. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated with vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67(9), 1322-1327 (2008).
42. Gillard P, Huurman V, Van der Auwera B et al. Graves hyperthyroidism after stopping immunosuppressive therapy in Type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care 32(10), 1817-1819 (2009).
43. Sloka JS, Phillips PW, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J. Autoimmune Dis. 2, 9 (2005).
44. Munteis E, Segura N, Martinez J, Cuadrado E, Galvez A, Roquer J. Idiopathic thrombocytopenic purpura in patients with multiple sclerosis. Mult. Scler. 12, S210 (2006).